Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The European Medicines Agency (EMA) on Wednesday released for consultation a new draft guideline to assist sponsors and investigators looking to comply with the requirements of the clinical trial master file (TMF), which includes documentation to allow monitoring by the sponsor and member state inspections.
"This guideline aims to collate and explain the requirements for the TMF as covered in the Regulation [(EU) No 536/2014] and ICH-GCP E6 to assist organisations in maintaining a TMF that facilitates trial management, GCP [good clinical practice] compliance and inspection. The document also addresses archiving of the TMF, clarifying retention times, in particular expectations in case of digitization and consecutive destruction of paper documentation," EMA notes.
Sponsors and investigators are expected to keep the TMF up to date and ensure that it is complete at the end of a trial, EMA says, noting that sponsors are also recommended to conduct routine quality assurance checks of the TMF.
In terms of preparing for a TMF inspection, the guideline says inspectors should have read-only access, though organizations "should be aware that GCP inspectors may have rights to seize original trial documentation if circumstances arise that require it."
And according to Article 58 of the clinical trial regulation, the sponsor and the investigator "shall archive the content of the clinical TMF for at least 25 years after the end of the clinical trial."
Draft guideline on good -clinical -practice compliance in relation to trial master file (paper and/or electronic) for content, management, archiving, audit and inspection of clinical trials
Tags: trial master file, EMA guideline